ArticleScience (New York, N.Y.)2025
Bile acid synthesis impedes tumor-specific T cell responses during liver cancer.
Abstract read
In one paragraph
Article in Science (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers.
0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed.
- The gut microbiome-bile acid-FXR interplay: a pivotal axis in metabolic and gastrointestinal diseases.Gut microbes · 2026Review
- Lithocholic acid alleviates fatty liver in mice and non-human primate macaques.Life metabolism · 2026Article
- Screening of known gut microbiome-derived metabolites in anti-tumor immunity of colorectal cancer.Journal for immunotherapy of cancer · 2026Article
- Microbial Signals in Cancer: Dissecting Host-Microbiota-Tumor Interactions and Potential Therapeutic Strategy.MedComm · 2026Review
- Exercise Modulates Microbial Metabolites and Induces Stromal Remodeling in Pancreatic Cancer.Cancer research · 2026Article
- Extended-Release Immunotherapy-Eluting Embolics.Cancers · 2026Article
- Subclinical cholestasis is a hallmark of gut dysbiosis causing resistance to cancer immunotherapy.Cancer cell · 2026Article
- Metabolic adaptations of the tumor macroenvironment and their role in cancer progression and survivorship.Genes & development · 2026Review
- EID1 blockade potentiates immunosurveillance against cancer metastasis via FPR1-mediated DC-NK crosstalk.Science China. Life sciences · 2026Article
- Palmitate promotes liver metastases by decreasing neutrophil antitumour behaviour.Nature metabolism · 2026Article
- Gut Microbiota, Immunity, and Metabolism in the Progression From Chronic Liver Disease to Hepatocellular Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The interplay between lipid metabolism, cancer progression and anti-cancer immunity.Experimental & molecular medicine · 2026Review
- Chenodeoxycholic acid restrains tumor growth via TGR5-dependent type 1 dendritic cells cross-priming.Signal transduction and targeted therapy · 2026Article
- Radiopaque microsphere-hydrogel composite for extended-release intratumoral immunotherapy in a large animal model.Drug delivery and translational research · 2026Article
- Lithocholic acid-activated VDR in macrophages promotes HCC recurrence post-ablation via SOCS3-mediated suppression of CXCL16.Journal for immunotherapy of cancer · 2026Article
- Crosstalk between CD8+ T cells and systemic bile acid metabolism shapes antiviral immunity and immunopathology.JCI insight · 2026Article
- Resveratrol Alleviates Arsenic-Induced Liver Fibrosis in Rats by Correcting SIRT1-Mediated Disorder of Hepatic Bile Acid Metabolism.International journal of molecular sciences · 2026Article
- Decoding the microbiome-immune crosstalk in cancer: from mechanisms to therapeutic translation.Biomarker research · 2026Review
- Harnessing the gut microbiota to enhance immune checkpoint inhibitor efficacy: from mechanistic insights to clinical translation.Molecular biology reports · 2026Review
- Glycodeoxycholic acid inhibits hepatocellular carcinoma by driving M1 polarization of macrophages via the S1PR2-NF-κB-NLRP3 pathway.JHEP reports : innovation in hepatology · 2026Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
33 authors.
Siva Karthik VaranasiNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0001-5797-2984
Dan ChenNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0001-5156-6635
Yingluo LiuDepartment of Pathology, School of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0009-0009-5704-063X
Melissa A JohnsonNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0002-6913-6059
Cayla M MillerDepartment of Pathology, School of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0001-8382-0255
Souradipta GangulySanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0002-5149-7315
Kathryn LandeThe Razavi Newman Integrative Genomics and Bioinformatics Core Facility, Salk Institute for Biological Studies, La Jolla, CA, USA.
Michael A LaPortaNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0009-0001-0461-5614
Filipe Araujo HoffmannNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.
Thomas H MannNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0002-3821-1466
Marcos G TenecheSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0003-4785-7987
Eduardo CasillasNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0001-9968-565X
Kailash C MangalharaNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0001-7412-3095
Varsha MathewNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.
Ming SunNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0009-0006-3798-1772
Isaac J JensenDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-3107-3961
Yagmur FarsakogluNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.
Timothy ChenNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0009-0002-7003-2721
Bianca ParisiNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0001-5273-4354
Shaunak DeotaRegulatory Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0002-4862-7414
Aaron HavasSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0003-4291-8015
Jin LeeDepartment of Pathology, School of Medicine, University of California San Diego, La Jolla, CA, USA.
H Kay ChungNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0002-7028-2432
Andrea SchietingerImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3644-1687
Satchidananda PandaRegulatory Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0002-7855-0091
April E WilliamsThe Razavi Newman Integrative Genomics and Bioinformatics Core Facility, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0001-9281-8528
Donna L FarberDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0001-8236-9183
Debanjan DharSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0001-8739-3684
Peter D AdamsSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0002-0684-1770
Gen-Sheng FengDepartment of Pathology, School of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0003-1255-4708
Gerald S ShadelNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0003-2899-8717
Mark S SundrudDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.ORCID 0000-0002-4249-0525
Susan M KaechNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0003-1674-1420
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MVIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9MVIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Paula T Hammond · 1985 to 2026
$93.9MTranslational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3MViral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Reuben Shaw · 1985 to 2026
$82.8MTranscriptomics and Repertoire ProfilingP01AI106697 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Donna L. Farber · 2013 to 2026
$31.3MViral Assays CoreU19AI128949 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Peter Alan Sims · 2017 to 2026
$26.4MUC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4MProject 4: Interrogating and harnessing age-related IFN signaling and innate immunity in HCC prevention and therapyP01AG073084 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI PETER D. ADAMS, GERALD SHADEL · 2021 to 2026
$13.6MSan Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8MSan Diego Nathan Shock CenterP30AG068635 · NIA · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI SHADEL, GERALD · 2020 to 2024
$6.0MNuclear Receptor Control of T Cell Function in Discrete Intestinal MicroenvironmentsR01AI164772 · NIAID · UNIVERSITY OF FLORIDA · PI SUNDRUD, MARK SCOTT, WEAVER, CASEY T · 2021 to 2025
$4.5MNCATS NIH HHS KL2 TR001444NCI NIH HHS F31 CA278581NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014051NCI NIH HHS P30 CA014195NCI NIH HHS P30 CA023100NCI NIH HHS P30 CA023108NCI NIH HHS R01 CA240909NIAID NIH HHS P01 AI106697NIAID NIH HHS R01 AI143821NIAID NIH HHS R01 AI164772NIAID NIH HHS R21 AI151562NIAID NIH HHS U01 AI163063NIAID NIH HHS U19 AI128949NIA NIH HHS P01 AG073084NIA NIH HHS P30 AG068635NIDDK NIH HHS P30 DK120515NIDDK NIH HHS R01 DK133930NIDDK NIH HHS R01 DK137061NIH HHS S10 OD023689
Abstract
The metabolic landscape of cancer greatly influences antitumor immunity, yet it remains unclear how organ-specific metabolites in the tumor microenvironment influence immunosurveillance. We found that accumulation of primary conjugated and secondary bile acids (BAs) are metabolic features of human hepatocellular carcinoma and experimental liver cancer models. Inhibiting conjugated BA synthesis in hepatocytes through deletion of the BA-conjugating enzyme bile acid-CoA:amino acid
Indexed as
Bile Acids and SaltsCarcinoma, HepatocellularCD8-Positive T-LymphocytesEndoplasmic Reticulum StressImmune Checkpoint InhibitorsLiver NeoplasmsUrsodeoxycholic AcidAcyltransferasesAnimalsCell Line, TumorHepatocytesHumansImmunotherapyLithocholic AcidMiceOxidative StressAcyltransferasesBile Acids and SaltsImmune Checkpoint InhibitorsLithocholic AcidProgrammed Cell Death 1 ReceptorUrsodeoxycholic Acid
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.